Approach to the Treatment of Irritable Bowel Syndrome: Modulation of the Microbiota and Specific Medications

• Autor(a) principal: Silva Bueno , Larissa Fernanda
• Data de Publicação: 2024
• Outros Autores: Soares Aragão, José Henrique, Tobias da Silva , Ana Beatriz, Dias do Nascimento, Brenda, Jahel Meireles, Danilo
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Brazilian Journal of Implantology and Health Sciences
• Texto Completo: https://bjihs.emnuvens.com.br/bjihs/article/view/1649
• topic: Síndrome do Intestino Irritável; Modulação da Microbiota; Medicamentos Específicos.; rritable Bowel Syndrome; Microbiota Modulation; Specific Medications.

In this analysis, several therapeutic strategies for the treatment of Irritable Bowel Syndrome (IBS) are examined, with a focus on microbiota modulation and the use of specific medications. Initially, we highlight the effectiveness of recently developed pharmacological interventions, emphasizing their ability to control IBS symptoms and improve patients' quality of life. These emerging therapies not only aim to alleviate symptoms but also seek to address the underlying causes of the condition, taking into account the complex interaction between intestinal microbiota and environmental factors. In addition to pharmacological interventions, innovative approaches such as modulation of intestinal microbiota are being explored to restore the balance of affected gut flora in IBS. These strategies include the use of probiotics, prebiotics, and symbiotics, which have been shown to promote gut health and reduce IBS symptoms in some patients. Ongoing research in this field is crucial for identifying the most effective microbial strains and better understanding how they can benefit individuals with IBS. Furthermore, it is important to highlight the role of specific medications in the treatment of IBS, including antispasmodic agents, intestinal motility modulators, and visceral pain regulators. These medications aim to alleviate gastrointestinal symptoms such as abdominal pain, bloating, and changes in bowel movements, providing relief to patients affected by IBS. In summary, the approach to treating Irritable Bowel Syndrome is increasingly focused on microbiota modulation and the use of specific medications. The integration of these therapeutic strategies can offer a more comprehensive and personalized approach to IBS management, significantly improving patients' quality of life. However, further research is needed to fully understand the underlying mechanisms and optimize the use of these therapeutic interventions in clinical practice.